Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib (Macugen) for prevention of proliferative diabetic retinopathy
2007-006795-10Phase 4Terminated
- Sponsor
- Frimley Health NHS Foundation Trust
- Start
- Jul 2008
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of pegaptanib sodium in diabetic retinopathy (NPDR) (2 arms), sponsored by Frimley Health NHS Foundation Trust. Primary endpoints: Primary endpoint (24 months, design description) and Primary endpoint (12 months, registry field). Started Jul 2008; status: terminated.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on 2007-006795-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006795-10.